Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

被引：2

作者：

Eggermont, A. M. M. ^{[1
]}

Chiarion-Sileni, V. ^{[2
]}

Grob, J-J. ^{[3
]}

Dummer, R. ^{[4
]}

Wolchok, J. D. ^{[5
]}

Schmidt, H. ^{[6
]}

Hamid, O. ^{[7
]}

Robert, C. ^{[8
]}

Ascierto, P. A. ^{[9
]}

Richards, J. M. ^{[10
]}

Lebbe, C. ^{[11
,12
]}

Ferraresi, V. ^{[13
]}

Smylie, M. ^{[14
]}

Weber, J. S. ^{[15
]}

Taitt, C. ^{[16
]}

de Pril, V. ^{[17
]}

de Schaetzen, G. ^{[18
,19
]}

Suciu, S. ^{[18
,19
]}

Testori, A. ^{[20
]}

机构：

[1] Gustave Roussy Canc Campus Grand Paris, Oncol Surg, Villejuif, France

[2] IRCCS, IOV, Dept Dermatol, Melanoma Oncol Unit, Padua, Italy

[3] Aix Marseille Univ, Hop La Timone APHM, Dept Dermatol & Skin Canc, Marseille, France

[4] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland

[5] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, 1275 York Ave, New York, NY 10021 USA

[6] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark

[7] Angeles Clin & Res Inst, Clin Res, Los Angeles, CA USA

[8] Gustave Roussy Canc Campus Grand Paris, Dermatol Unit, Villejuif, France

[9] Fdn G Pascale, Ist Nazl Tumori, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy

[10] Oncol Specialists SC, Div Hematol Oncol, Park Ridge, IL USA

[11] Univ Paris 07, INSERM, U976, Hop St Louis,APHP,Dept Dermatol, Paris, France

[12] Univ Paris 07, INSERM, U976, Hop St Louis,APHP,CIC Dept, Paris, France

[13] Ist Fisioterapici Ospitalieri, Dept Med Oncol, Rome, Italy

[14] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada

[15] H Lee Moffitt Canc Ctr & Res Inst, Dept Med, Tampa, FL USA

[16] Bristol Myers Squibb, Worldwide Med, Princeton, NJ USA

[17] Bristol Myers Squibb, Worldwide Med, Braine Lalleud, Belgium

[18] EORTC Headquarters, Melanoma Grp, Brussels, Belgium

[19] EORTC Headquarters, Melanoma Grp, Brussels, Belgium

[20] European Inst Oncol, Div Melanoma & Sarcomi Muscolocutanei, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw435.35

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA2_PR

引用

页数：1

共 50 条

[41] FINAL OVERALL SURVIVAL RESULTS FROM the DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED PHASE III PENELOPE TRIAL EVALUATING PERTUZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER WITH LOW TUMOUR HER3 mRNA EXPRESSION
Lorusso, D.
Gonzalez-Martin, A.
Lueck, H. J.
Rau, J.
Selle, F.
Colombo, N.
Ottevanger, P.
Mirza, M. R.
Berger, R.
Garcia-Donas, J.
Grischke, E. M.
Berton-Rigaud, D.
Redondo, A.
Vergote, I.
Poveda, A.
Bastiere-Truchot, L.
Cardona, A.
du Bois, A.
Kurzeder, C.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 11 - 12
[42] CA184-043: A randomized, multicenter, double-blind phase 3 trial comparing overall survival (OS) in patients (pts) with post-docetaxel castration-resistant prostate cancer (CRPC) and bone metastases treated with ipilimumab (ipi) vs placebo (pbo), each following single-dose radiotherapy (RT)
Gerritsen, W. R.
Kwon, E. D.
Fizazi, K.
Bossi, A.
Van den Eertwegh, A.
Logothetis, C.
Scher, H. I.
Beer, T. M.
McHenry, M. B.
Gagnier, P.
Drake, C. G.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S678 - S679
[43] Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
Weber, J. S.
Del Vecchio, M.
Mandala, M.
Gogas, H.
Arance, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J. J.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Butler, M. O.
Maio, M.
Middleton, M. R.
Tang, T.
Saci, A.
De Pril, V.
Lobo, M.
Larkin, J. M. G.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2019, 30 : 533 - +
[44] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Bottomley, Andrew
Coens, Corneel
Mierzynska, Justyna
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Puig, Susana
Ascierto, Paolo A.
Larkin, James
Lorigan, Paul C.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Di Giacomo, Anna Maria
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
Eggermont, Alexander M. M.
LANCET ONCOLOGY, 2021, 22 (05): : 655 - 664
[45] A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Weber, Jeffrey
Thompson, John A.
Hamid, Omid
Minor, David
Amin, Asim
Ron, Ilan
Ridolfi, Ruggero
Assi, Hazem
Maraveyas, Anthony
Berman, David
Siegel, Jonathan
O'Day, Steven J.
CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5591 - 5598
[46] KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu Sujata
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
de Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen Michael
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu Sujata
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
De Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen Michael
Lorusso, Domenica
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A420 - A420
[48] STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)
Bruix, Jordi
Takayama, Tadatoshi
Mazzaferro, Vincenzo
Chau, Gar-Yang
Yang, Jiamei
Kudo, Masatoshi
Cai, Jianqiang
Poon, Ronnie Tung-Ping
Han, Kwang-Hyub
Tak, Won-Young
Lee, Han Chu
Song, Tianqiang
Roayaie, Sasan
Bolondi, Luigi
Lee, Kwan Sik
Makuuchi, Masatoshi
Souza, Fabricio
Le Berre, Marie-Aude
Meinhardt, Gerold
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[49] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Bottomley, A.
Kicinski, M.
Long, G. V.
Mandala, M.
Atkinson, V. G.
Blank, C. U.
Haydon, A. M.
Dalle, S.
Khattak, A.
Carlino, M. S.
Meshcheryakov, A.
Sandhu, S. K.
Puig Sarda, S. S.
Coens, C.
Suciu, S.
Grebennik, D.
Krepler, C.
Lorigan, P.
Robert, C.
Eggermont, A. M. M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1410 - S1411
[50] Adjuvant Nivolumab (NIVO) Versus Ipilimumab (IPI) in Resected Stage III/IV Melanoma: 3-Year Efficacy and Biomarker Results From the Phase 3 Checkmate 238 Trial
Weber, J.
Del Vecchio, M.
Mandala, M.
Gogas, H.
Arance, A. M.
Dalle, S.
Cowey, C. L.
Schenker, M.
Grob, J.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Butler, M.
Maio, M.
Vetto, J.
Tang, H.
Saci, A.
de Pril, V.
Lobo, M.
Larkin, J.
Ascierto, P. A.
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S144 - S144

← 1 2 3 4 5 →